Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
altered, chain, chronic, condensed, elbow, fluid, footnote, hip, holding, inclusion, IND, leadership, legacy, nondeductible, oral, overuse, paymentsrelated, paymentunder, repeal, repetitive, robust, rolling, RSU, scaffold, secondary, simplification, site, sixteen, synovial, unissued, wasprimarily
Removed:
abandonment, Administration, affiliated, agreed, AMVISC, announced, Bausch, BCDI, Biotech, closure, dispute, EMA, engineering, expanded, expectation, fee, improvement, incur, Johnson, jurisdiction, Lomb, member, minimum, noncash, Ortho, penetrate, prioritize, region, renewed, revise, shift, stability, thereof, therewith, titled, vulnerable
Filing tables
Filing exhibits
Related press release
ANIK similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-06275, 333-66831, 333-79047, 333-58264, 333-110326, 333-160102, 333-176103 and 333-190597) of Anika Therapeutics, Inc. of our report datedFebruary 24, 2017relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 24, 2017